Nipocalimab Improves gMG Outcomes Across East Asian Subgroup

Nipocalimab produced consistent improvements in adults with generalized myasthenia gravis (gMG) among East Asian patients, comparable with the overall population in the Vivacity-MG3 study, according to a subgroup analysis published in the Journal of Clinical Neurology.¹ However, the East Asian subgroup’s smaller sample size left the findings with wider margins of uncertainty in comparison to the full trial. Researchers also found population-specific differences, including a lower placebo response rate, warranting further study.

New FDA-Approved gMG Treatment

Myasthenia gravis (MG) is a chronic autoimmune disease that affects the neuromuscular junction, the connection point between nerves and muscles. It happens when the body’s own autoantibodies mistakenly target proteins involved in muscle signaling, such as the acetylcholine receptor (AChR) and muscle-specific kinase (MuSK). MG causes muscle weakness and fatigue and is categorized into 2 forms: ocular MG, which affects only the eye muscles (15% of cases), and gMG, which affects a broader range of muscles and makes up the remaining 85% of cases.

Access to newer gMG therapies is still limited in certain regions of Asia due to reimbursement constraints, and existing treatments can come with side effects or complex dosing regimens. Nipocalimab (Imaavy; Johnson & Johnson), a new FDA-approved drug,² is a fully human monoclonal antibody that binds to the neonatal Fc receptor (FcRn) with high affinity. The FDA approved the treatment for gMG in adults and pediatric patients 12 years or older who are AChR-positive or MuSK-positive. Nipocalimab works by blocking the interaction between immunoglobulin G (IgG) and FcRn, reducing circulating antibody levels while preserving the rest of the immune function and avoiding broad immunosuppression associated with some older therapies.

Clinical Trial for East Asian Patients With gMG

The Vivacity-MG3 study was a phase 3, multicenter, double-blind, randomized study conducted in 17 countries. This subgroup analysis presents results from the East Asian territories. Of the 248 people screened, 199 individuals were randomized 1:1 using an interactive web response system. Of these participants, 100 were assigned to nipocalimab and 99 to placebo.³ Randomization was balanced using randomly permuted blocks and stratified by the following factors: antibody status, day 1 Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score, and region. Participants, investigators, and the study sponsor were blinded to treatment assignment, and results reflect only the 24-week double-blind phase.

Of the trial’s 199 participants, only 56 were part of the Asian subgroup (28 assigned to nipocalimab and 28 to placebo), and just 48 of the 153 global antibody-positive participants were part of the Asian subgroup. Nipocalimab was given as a 30 mg/kg loading dose followed by 15 mg/kg every 2 weeks via IV infusion; the placebo was administered similarly.

Nipocalimab Treatment Response Rate

The study’s primary end point, the least-squares mean difference in change from baseline in MG-ADL over weeks 22 to 24 between nipocalimab and placebo groups, was –1.35 (95% CI –2.93 to 0.24) in favor of nipocalimab in the Asian population, consistent with the overall population, where the difference was –1.45 (95% CI –2.38 to –0.52). Because the Asian subgroup’s efficacy dataset included only 48 patients compared with 153 overall, its CI was wider, reflecting greater statistical uncertainty.

A secondary end point, the Quantitative Myasthenia Gravis score, showed a similar pattern: the least-squares mean difference in change from baseline over weeks 22 to 24 between the nipocalimab and placebo groups was –2.73 (95% CI –5.12 to –0.34) in the Asian population and –2.81 (95% CI –4.22 to –1.41) in the overall population. In the Asian subgroup, 20.8% more patients in the nipocalimab group achieved a 50% or greater improvement in averaged MG-ADL total score over weeks 22 to 24, consistent with the 21.8% observed in the overall population.

Researchers additionally tracked total IgG levels throughout the trial for the subgroup. By week 24, the median percent change from baseline was –61.1% in the nipocalimab group, compared with 2.3% in the placebo group, confirming the drug was suppressing antibody levels.

Nipocalimab Adverse Events

Treatment-emergent adverse event rates in the Asian subgroup were similar between treatment arms and aligned with those observed in the overall population. Any adverse event (AE) was reported in 24 patients (85.7%) in each treatment group, and serious AEs occurred in 3 patients (10.7%) in each arm, with only one event in the placebo group considered related to the study treatment. One placebo patient (3.6%) discontinued treatment due to an AE; no nipocalimab patients did.

During the study period, 10 patients (35.7%) in the nipocalimab group and 8 (28.6%) in the placebo group experienced an infection. Worsening gMG occurred in 2 patients (7.1%) in each treatment arm, and headache occurred in 3 patients (10.7%) in each arm. Muscle spasms (n = 2; 7.1%) and peripheral edema (n = 5; 17.9%) occurred only in the nipocalimab group. No serious AEs were considered related to nipocalimab, and no patients discontinued nipocalimab due to an AE.

gMG Treatment Access in Asia

These findings support the conclusion that nipocalimab, added to standard-of-care therapy, provides meaningful clinical benefits for East Asian patients with gMG who had an inadequate response to prior treatment, a pattern consistent with what researchers observed in the trial's overall population. Asian patients in the placebo group responded less strongly than placebo patients in the overall trial population across several measures: overall response, early response, sustained response, and the share reaching a 50% or greater MG-ADL improvement. However, the gap was most pronounced in how quickly symptoms improved.

The study’s authors suggest the findings point to the need for future trials in this population to pay close attention to trial design and the doctor-patient relationship, recommending pooled analyses across multiple MG trials or region-specific research to help understand the varying placebo responses.

Subgroup Analysis Limitations

The study comes with several limitations. The findings are specific to the East Asian patients studied and haven’t been confirmed in other populations. With only 56 patients, it’s difficult to confidently determine whether the difference between the drug and placebo groups is a true treatment effect or is simply due to random chance. With fewer patients, the CIs around these results are also wider, adding further uncertainty.

Baseline imbalances between treatment arms within the subgroup may have also influenced results, and subjective, self-reported assessments like MG-ADL can be swayed by placebo affects. The study tracked patients for only 24 weeks, so long-term effects remain unknown. Despite these limitations, the findings offer useful early evidence supporting nipocalimab’s potential benefit for East Asian patients with gMG.

Open-Label Extension Study

Given the subgroup’s small sample size, there is still a need for larger, real-world studies with longer follow-up to confirm these results and refine treatment approaches specifically for East Asian patients. The trial’s open-label extension phase is underway and expected to provide additional insight into how durable nipocalimab’s benefits are in the long term. Interim data presented at the American Academy of Neurology’s 2025 annual meeting showed sustained disease control as far out as 72 weeks.²

Durability, in addition to early symptom relief, is a central part of nipocalimab’s role in gMG care, explained Constantine Farmakidis, MD, a neuromuscular specialist and associate professor at the University of Kansas Medical Center and a co-author of the original Vivacity-MG3 trial.³

"The treatment goal in MG is to first achieve disease control and then to have disease control be durable,” Farmakidis said. “The open-label extension data for nipocalimab in MG showed evidence of durable disease control. This is a very encouraging finding."

References

1. Nagane Y, Yang H, Park JS, Yeh JH, Turkoz I, Makanji Y. Efficacy and safety of nipocalimab in adults with generalised myasthenia gravis: an Asian subgroup analysis of the Vivacity-MG3 study. J Clin Neurol. 2026;22(4):446-455. doi:10.3988/jcn.2025.0290
2. Mattina C. FDA approves nipocalimab for generalized myasthenia gravis. AJMC. April 30, 2025. Accessed July 14, 2026. https://www.ajmc.com/view/fda-approves-nipocalimab-for-generalized-myasthenia-gravis
3. Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116
4. Shaw ML, Farmakidis C. A closer look at nipocalimab's impact on myasthenia gravis care: Constantine Farmakidis, MD. AJMC. July 3, 2025. Accessed July 14, 2026. https://www.ajmc.com/view/a-closer-look-at-nipocalimab-s-impact-on-myasthenia-gravis-care-constantine-farmakidis-md